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Breath and plasma metabolomics 
to assess inflammation in acute 
stroke
Waqar Ahmed1,2,9, Iain R. White1,3,9, Maxim Wilkinson1,2, Craig F. Johnson2, 
Nicholas Rattray4, Amit K. Kishore5,6, Royston Goodacre7, Craig J. Smith5,6,10* & 
Stephen J. Fowler1,8,10*
Inflammation is strongly implicated in both injury and repair processes occurring after stroke. In 
this exploratory study we assessed the feasibility of repeated sampling of exhaled volatile organic 
compounds and performed an untargeted metabolomic analysis of plasma collected at multiple time 
periods after stroke. Metabolic profiles were compared with the time course of the inflammatory 
markers C-reactive protein (CRP) and interleukin-6 (IL-6). Serial breath sampling was well-tolerated 
by all patients and the measurement appears feasible in this group. We found that exhaled decanal 
tracks CRP and IL-6 levels post-stroke and correlates with several metabolic pathways associated 
with a post-stroke inflammatory response. This suggests that measurement of breath and blood 
metabolites could facilitate development of novel therapeutic and diagnostic strategies. Results are 
discussed in relation to the utility of breath analysis in stroke care, such as in monitoring recovery and 
complications including stroke associated infection.
Stroke is the second leading cause of death  worldwide1 and the leading cause of adult neurological  disability2. 
The onset of cerebral ischaemia induces an inflammatory response in the central nervous system (CNS) and 
periphery, characterised by activation of resident CNS immune cells, recruitment of peripheral leucocyte popu-
lations and a systemic acute phase  response3. Inflammation is strongly implicated in both the injury and repair 
processes occurring after stroke and may represent opportunities for therapeutics. Numerous inflammatory 
mediators in the peripheral circulation, such as C-reactive protein (CRP) and interleukin-6 (IL-6), are altered 
in the acute phase of stroke and could have a role as biomarkers of prognosis or impending  complications4,5.
Advances in sampling and analytical methods have led to the successful application of metabolomics in several 
inflammatory  diseases6,7. Biomarkers that reflect disruption of metabolic pathways after stroke could facilitate 
development of novel therapeutic and diagnostic  strategies8. An alternative non-invasive approach to monitor-
ing post-stroke complications is to analyse exhaled volatile organic compounds (VOCs). Breath analysis offers 
a biologically relevant systems-approach, which has shown promise in detecting relevant airway pathogens in 
mechanically ventilated  patients9–11. Serial breath sampling in non-ventilated acute stroke patients is however 
potentially challenging, as altered awareness, cognitive and language difficulties, impaired sitting balance and 
hemi-facial weakness are frequently encountered.
Infections are the most common complication of stroke and exacerbate the inflammatory  response12. Pneu-
monia is the most frequent infection, occurring in around 14% of patients, and as many as 35% of those at 
highest  risk13, and independently predicts death and worse outcomes in  survivors14. At present, existing blood 
biomarkers add little to clinical prediction  algorithms15, and development of biomarkers to enable early detection 
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of pneumonia and response to antibiotic treatment would have considerable value in stroke care and antibiotic 
stewardship. A range of VOCs have been identified in previous studies as potential markers of  infection9,16 and 
 inflammation17,18, and could therefore have value in the setting of acute stroke.
We therefore conducted a study to assess the feasibility of combined breath and plasma sampling for metabo-
lomic analysis in patients admitted to hospital after acute stroke. The primary objective was to refine our existing 
breath sampler methodology for use in the acute stroke setting and establish the feasibility of alternate-day breath 
sampling during a relevant timeframe after admission. A secondary objective was to explore contemporaneous 
exhaled breath, plasma metabolomic and cytokine profiles in patients considered at high-risk of developing 
pneumonia.
Methods
Study assessment schedule. The study schedule was based on the course of the most frequently encoun-
tered complications of stroke. Infections, particularly pneumonia, occur most frequently within the first week 
after stroke onset, and antibiotic treatment is typically prescribed for at least 5–7 days. Our breath sampling 
schedule was therefore designed to evaluate the feasibility of repeated measurements starting within 24 h of 
symptom onset, and on alternate days to day 15 (or discharge from inpatient stroke services if this occurred 
sooner). Each participant underwent a maximum of eight scheduled breath sampling and clinical assessments. 
This schedule would be appropriate aimed obtain breath measurements prior to the clinical manifestation of 
pneumonia, during clinical investigation of suspected pneumonia, and both during and after antibiotic therapy. 
This timeframe also incorporates the peak in levels of inflammatory mediators.
Study participants. Patients with ischaemic stroke or intracerebral haemorrhage (ICH) presenting to the 
Comprehensive Stroke Centre (CSC) at Salford Royal Hospital within 24 h of the onset of stroke symptoms were 
screened for inclusion. In order to assess the risk of developing pneumonia, we used the  A2DS2 score, a 10 point 
clinical score based on age, presence or absence of atrial fibrillation, dysphagia, sex and stroke  severity19. The 
 A2DS2 score is an externally validated risk score in stroke patients with good performance  metrics20. Patients 
aged over 17 years, with an ischaemic stroke or ICH and an  A2DS2 score of ≥ 3 were eligible. Informed consent 
was provided by participants, or by a personal consultee in situations where capacity was lacking. Approvals 
were obtained from the Betsi Cadwaladr University Health Board regional ethics committee (Ref: 14/WA/0018) 
and Trust Research and Development department. All research methods were performed in accordance with 
the relevant guidelines and regulations. The CSC at Salford Royal operates a hub and spoke model, and patients 
residing outside the local area who present to the CSC in the hyperacute or acute phase are repatriated to their 
base hospital after completion of an acute care bundle. Therefore, only patients with a Salford area postcode were 
considered for screening (to avoid early repatriation of participants to their base hospital). Patients were addi-
tionally excluded for any of the following reasons: (1) informed consent was not possible; (2) rapidly improving 
symptoms at the time of screening; (3) infection treated with antibiotics in the preceding 6 weeks; (4) mechanical 
ventilation or palliative care considered imminent. A secure log was kept of all patients screened for the study, 
including the reason for non‐inclusion.
Clinical assessments. Baseline stroke subtype (ischaemic stroke or ICH), stroke severity using the 
National Institutes of Health Stroke Scale (NIHSS)21 score, swallowing status, vascular risk factors, medications, 
independence pre-stroke using the modified Rankin score (mRS)22 and vital signs were recorded at study entry. 
In addition, swallowing and feeding status, oxygen requirements, vital signs, standardised infection screening 
log, antibiotic prescriptions, microbiology data, chest radiography results and any antibiotic prescriptions were 
recorded by the study team on each scheduled study assessment. Clinician-diagnosed and treated infections 
were adjudicated by the study team using the Centers for Disease Control and Prevention (CDC)  criteria23. End 
of study mRS was recorded at day 15, or at discharge if this occurred earlier.
Development of the breath sampler for stroke unit setting. The sampler was designed as a portable 
system capable of supplying VOC-filtered air to a breathing mask, providing constant airflow. The method and 
sampler components were based on our previous  sampler24 but the integration of new components resulted in 
a smaller footprint such that the complete system along with accessories and laptop could be transported to the 
bedside on a standard hospital trolley. Briefly, air is supplied through a one-way non re-breathing valve to a mask 
(ResMed, Mirage Full Mask Series 227, Resmed, Abington, UK) via a VOC filter (AX:456-06-20, 3M, Bracknell, 
UK) and an adapted CPAP machine (Resmed Stellar, Resmed). Pressure sensors at the patient interface allow 
tracking of the breathing cycle and enable targeted sampling of the late expiratory phase even with variable 
breathing patterns. During sampling, breath is diverted through a 3.5″ stainless steel tube containing a dual 
bed of sorbent material for VOC capture (Carbograph 2TD 40/60 mesh, Carbograph 5TD 40/60 mesh; Markes 
International, UK) using a diaphragm pump (Escort ELF Pump, MSA) at a flow rate of 1 L  min−1. A picture of 
the breath sampler is shown in supplementary material, Fig. S1.
Breath sampling and analyses. All breath sampling was undertaken by stroke research nurses trained 
and assessed in the sampling procedure. After each participant was fitted with the mask they were allowed to 
acclimatise to the system for 10 min prior to breath collection. Approximately 2 L of late-expiratory breath was 
sampled through each sorbent tube. To minimise the potential impact of diurnal  variation25, all breath sampling 
after study entry was between 07:00 and 11:30. Following breath sampling, tubes were immediately sealed and 
stored at 4 °C until the time of their analysis.
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A gaseous standard (100 μL of 1 ppmV 4-bromofluorobenzene in nitrogen; Thames Restek, UK) was added 
to each sorbent tube as an internal standard prior to analysis by thermal desorption-gas chromatography-time of 
flight-mass spectrometry (TD-GC-ToF-MS). Tubes were thermally desorbed at 280 °C for 5 min in 50 mL  min−1 
of carrier gas and cryo-focussed onto a cold trap maintained at 10 °C. Analytes were then desorbed from the 
cold trap at 280 °C for 3 min and transferred to a GC oven (6890 series, Agilent, UK) via a heated transfer line 
maintained at 200 °C. Flow to the column (DB-5MS, 30 m, 0.25 mm I.D., 0.25 μm film thickness, Agilent) was 
maintained at 1 mL  min−1 and the oven was set to an initial temperature of 40 °C (no hold time), with a primary 
ramp to 170 °C at 6 °C  min−1 and a secondary ramp to 190 °C at 15 °C  min−1 with a total run of 23 min (followed 
by a 2 min post-run at 250 °C). Analytes were detected by time of flight mass spectrometry (Micromass GCT 
Premier, Waters, UK) with an electron ionisation source at 70 eV. The source temperature was set to 200 °C, 
at a trap current of 200 μA and spectra were recorded in dynamic range extension mode at 10 Hz over a range 
of 50–650 m/z. The  [C4F9]+ fragment of heptacosafluorotributylamine was used as a lock mass (218.9856 Da). 
Samples were analysed in random order and each patient sample was analysed alongside a 24-component external 
 standard26. A further 22 compounds, selected from literature as markers of infection and inflammation, were 
included in a target list and peak areas were extracted based on accurate mass fragments (Table S1).
The following quality control criteria were adopted to ensure exhaled VOCs could be precisely quantified: 
1. Internal standard parent ions (m/z 173.9480 and 175.9460) did not deviate by more than 5% within a batch, 
in abundance or ratio (to ensure that any water remaining on the tubes after their pre-purge had not affected 
analyses); 2. If the sum total-ion-count of a chromatogram (once background subtracted for the lock-mass 
compound) deviated by more than 10% within in a batch, this run was flagged. These samples were then rejected 
from further data analysis if dodecamethylcyclohexasiloxane was not detected (at m/z = 429 at a retention time 
of 15.90 min). None of the samples were rejected due to water retention however several were discarded due to 
low VOC recovery, most likely due to the irreversible sorption of semi-volatile compounds onto the strongest 
sorbent following inadvertent sampling in reverse orientation. Whilst simple strategies can be adopted to abate 
this problem, it is only apparent after thermal desorption and highlights an important consideration for future 
studies given that multi-bed sorbent tubes are currently a common choice in breath  research27.
Blood sampling and analyses. Venous blood was drawn at study entry, day 3, day 5–7 and day 15 for 
analysis of plasma metabolomics, IL-6, CRP, total white blood-cell (WBC) count and automated differential 
leukocyte counts. Blood draw was standardised between 07:00 and 11:00, except for study entry. For plasma 
analyses, blood was collected in 4.5 mL heparinised tubes (for metabolomics) and 6 mL EDTA (for CRP and 
IL-6), centrifuged at 2000×g at 4 °C for 15 min, and frozen at − 70 °C. An additional 3–4 mL of blood was col-
lected in EDTA for total WBC and automated differential using the Coulter principle.
Plasma IL-6 was measured using Luminex bead technology (Luminex, Austin, TX, USA). Bio-Plex COOH 
beads (Bio-Rad Laboratories, Hemel Hempstead, UK) were coupled to Pelikine anti-IL-6 monoclonal antibodies 
(Cat: M191602, MAST Group Ltd, Bootle, UK). The detection antibody was Pelikine anti-IL-6 (Cat: M191604) 
and 15% horse serum, 5% bovine serum, and 1% mouse serum in high performance ELISA buffer (HPE; Pelikine) 
was used as diluent. Plasma CRP was measured in a single-plex competitive assay using Luminex bead technol-
ogy (Luminex, Austin, TX, USA). Bio-Plex magnetic COOH beads (Bio-Rad Laboratories, Hemel Hempstead, 
UK) were coupled to Biodesign anti-CRP monoclonal antibody (cat: M86842M, clone C2). The competitor 
was CRP (P100-0; SCIPAC, Sittingbourne, UK) biotinylated with Pierce EZ-Link Sulfo-NHS-LC-LC-Biotin 
(Pierce, Rockford, IL, USA). 10% horse serum, 5% bovine serum, and 1% mouse serum in tris-buffered saline 
was used as diluent. Binding of biotinylated CRP or IL-6 detection antibody was assessed, following addition 
of R-Phycoerythrin Streptavidin (Jackson ImmunoResearch Laboratories Inc, Stratech, Newmarket, UK; Cat: 
016-110-084), using a Bio-Plex 200 system. The assays were calibrated against current National Institute for 
Biological Standards and Control standards (NIBSC, South Mimms, UK) standards.
Plasma metabolomic analysis was performed using ultra-high performance liquid chromatography-mass 
spectrometry (UHPLC-MS). Samples were lyophilised by drying the supernatant from protein precipitation with 
LC-MS grade methanol (1:4 ratio plasma:methanol). Lyophilised sample pellets were reconstituted in LC-MS 
grade water (100 μL) and added to LC-MS clear vials with fixed inserts. Analysis was carried out on an Accela 
UHPLC auto-sampler coupled to an electrospray LTQ-Orbitrap XL hybrid mass spectrometer (Thermo Fisher, 
Bremen, Germany), following established  protocols28. Xcalibur and TunePlus software (version 2.0, Thermo 
Fisher, Bremen, Germany) were used for instrument operation. Tuning and calibration was carried out as per 
the manufacturer’s instruction. Samples were analysed in a random order whereby 5 μL aliquots were injected 
onto a Hypersil Gold C18 reversed phase column (100 mm × 2.1 mm × 1.9 μm) and a methanol/water solvent 
gradient was used to separate metabolites on the stationary phase (95% water 5% methanol for solvent A and 5% 
water 95% methanol for solvent B). Both solvents contained 0.1% formic acid to aid ionization within the source. 
Samples were analysed in positive ESI mode using the following settings: 1 micro scan per 400 ms, 50–2000 m/z 
range, source transfer tube set at 275 °C, tube lens voltage set at 100 V, capillary voltage set at 30 V, sheath gas 
flow rate set at 40 arbitrary units, auxiliary gas flow set at 5 arbitrary units and sweep gas at 1 arbitrary units. 
Data were collected in profile mode at a mass resolution of 30,000.
Breath sampling feasibility. The feasibility of the breath sampling protocol was evaluated by recording 
the proportion of eligible patients declining participation (and reasons given), time taken to undertake breath 
sampling, and the proportion of participants completing alternate day breath sampling from study entry to 
end-of study as per sampling protocol. Sampling reliability was assessed by calculating intraclass correlation 
coefficients (two way) across selected timepoints (n = 4) for patients without missing visits (n = 5). An ICC of 
less than 0.5 was interpreted as poor, between 0.5 and 0.74 as moderate, and greater than 0.75 as good. Nega-
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tive ICC values were interpreted as 0. The tolerability of serial breath analysis was assessed as the proportion of 
participants unable to complete the breath sampling protocol on one or more occasions (and reasons given if 
not completed). Data were described using appropriate summary statistics. We planned additional exploratory 
secondary analyses to investigate the presence of previously published pathogen-associated metabolites detected 
in exhaled breath, plasma or both. As this was a feasibility study, a power calculation was not performed. Instead 
we estimated that recruitment of at least 20 patients meeting the eligibility criteria would enable assessment of 
the primary aims of feasibility and tolerability.
In order to compare the progression of VOC profiles alongside blood metabolites and inflammatory cytokines 
post-stroke onset, data were binned into four time-periods as depicted in Fig. 1.
Data pre-processing and treatment. Blood plasma sample data were converted to netCDF format 
and pre-processed using the XCMS Centwave peak picking  algorithm29 and LOESS retention time correction. 
Pooled QC sample data were used to align instrument drift through Robust Spline  Correction30. Data were then 
treated by  log10 transformation and autoscaling. For exhaled VOCs, selected ion peak areas were extracted and 
normalised across all breath samples using TargetLynx software (Masslynx version 4.1, Waters Corporation, 
UK). Non-detected VOC peak areas (total n = 108) were treated as missing values and excluded from statistical 
tests. The R packages employed in this study were xcms31, corrplot, irr, tidyverse, and adegenet32.
Statistical analysis. Univariate and multivariate statistical analyses were performed in R (version 3.5) 
and Graphpad Prism (version 7.03). The non-parametric multiple comparisons Kruskal–Wallis test was used 
to screen breath VOCs and inflammatory markers across timepoint samples by comparing mean peak  areas33. 
For significant differences, a post-hoc Dunn’s test was used to further explore change in peak area between 
two groups. False discovery rate was used to adjust for multiple comparisons in all other analyses. To model 
discriminatory plasma features based on post-stroke sampling time, supervised classification Principal Compo-
nent-Discriminant Function Analysis (PC-DFA) was carried out; this maximised inter-group variation whilst 
minimising intra-group  variation34. Model parameters (number of PCs = 15, and number of discriminant func-
tions = 4) were cross-validated using stratified random sampling (× 1000 sample replications). Pearson’s r was 
used to evaluate correlations between inflammatory markers, VOCs and plasma metabolites.
Metabolite identification. Identification of selected VOC compounds was confirmed using chemical 
standards in agreement with the metabolomics standards initiative for chemical  analysis35,36. Specifically, VOCs 
with two orthogonal means of identification (i.e. chemical standards and mass spectra library search (NIST 05)) 
were annotated as level 1, whereas identification solely based on a mass spectra library search and retention 
index were classified as level 2.
All plasma metabolites were annotated as MSI level 2 as identification was based on accurate mass data. 
Plasma metabolite identification was predicted through molecular networking using the online version of Mum-
michog37. Each feature from pre-processed data was subjected to a Kruskal Wallis test to assess differences 
between the mean of timepoint groups. The resulting list of m/z values, retention times, and FDR adjusted p 
values was used as input for molecular network analysis. Thresholds of m/z differences were set to 10 ppm. All 
features were annotated with positive ion mode adducts such as [M + H] + and [M + Na] + . Using these data, 
features are annotated with an Empirical identification (EID) based on concerted metabolite activities, which 
Figure 1.  Study assessment overview depicting the type and number of samples collected.
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are clustered based on similarities and mapped to known metabolic pathways and ordered based on significance 
through a permutation test (α < 0.05). Cytoscape 3.4.038 was used to visualise network maps.
Results
Screening, recruitment and participant characteristics. During the study recruitment period (8 
September 2014 to 31 March 2016), we screened 72 patients, of whom 33 were eligible. Of these, informed 
consent was obtained for 20 participants (Fig. 1). Of the remaining 13 patients, nine declined participation (six 
due to lack of interest in the study and three due to lack of interest in research participation in general) and it 
was not possible to obtain informed consent directly from the patient (and a consultee was not available) in the 
other four.
The baseline characteristics of the 20 participants are shown in Table 1. The majority of patients were dys-
phagic at study entry with moderate severity stroke. Four of the 19 patients (21%) with ischaemic stroke received 
intravenous thrombolysis. There were no physician-diagnosed or CDC-confirmed episodes of pneumonia during 
the period of breath sampling. There were six CDC-confirmed urinary-tract infections (UTIs) in five participants 
occurring at a median (min, max) of 9 (3, 15) d.
Feasibility and tolerability of serial breath sampling. The median (min, max) time from stroke symp-
tom onset to first breath sampling was 16.5 (6.0, 23.8) h. Of the 20 participants, 11 (55%) remained inpatients 
at the CSC at least to their day 15 assessment, completing all 8 scheduled assessments. The median (min, max) 
end-of study mRS was 4 (0, 5). One participant deteriorated prior to their day 5 assessment, requiring intubation 
and ventilation due to significant bulbar involvement and retained respiratory secretions (but no subsequent 
confirmed pneumonia) and was withdrawn from the study by the research team. The remaining 8 participants 
were discharged from the CSC prior to the day 15 assessment, but after completing the day 3 (3 participants), day 
5 (3 participants), day 7 (1 participant) and day 13 (1 participant) assessments with breath sampling. Therefore, 
in total 116 breath samples were collected from the 20 participants; all sampling episodes were well-tolerated 
and completed successfully. Overall, the median (min, max) number of breath samples per participant was 8 (2, 
8). During the study, 8 participants (40%) had a nasogastric tube in situ and 4 (20%) others had supplemental 
Table 1.  Baseline characteristics of the participating patients. Data shown as mean ± SD or median (min, max) 
except where indicated;  A2DS2 score: Age, Atrial Fibrillation, Dysphagia, Sex, stroke Severity.
Total number of participants, n 20
Age/[years] 71.7 ± 14.5
Male sex, n (%) 12 (60)





Stroke type, n (%)
Ischaemic 19 (95)
 Total anterior circulation infarct 10 (50)
 Partial anterior circulation infarct 4 (20)
 Posterior circulation infarct 3 (15)
 Lacunar infarct 2 (10)
Intracerebral haemorrhage 1 (5)
Glasgow Coma Scale score 14 (9, 15)
A2DS2 score 6 (3, 10)
Nil by mouth, n (%) 12 (60)
Vascular risk factors, n (%)
Hypertension 15 (75)
Diabetes mellitus 2 (10)
Previous stroke or transient ischaemic attack 5 (25)
Coronary artery disease 7 (35)
Atrial fibrillation 9 (45)
Hyperlipidaemia 11 (55)
Current smoker 4 (20)
Preceding modified Rankin score 0 (0, 4)
Total white blood cell count/[109  L−1] 9.2 (6.7, 11.8)
Plasma C-reactive protein/[mg  L−1] 4.8 (0.1, 26.2)
Plasma interleukin-6/[pg  mL−1] 6.0 (2.6, 40.5)
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oxygen provided via nasal cannulae on at least one occasion during breath sampling. The median (min, max) 
duration of breath sampling at the bedside was 6 (3, 30) min. Intraclass correlation coefficients showed good 
intra-patient reliability for VOCs commonly found in breath samples and poor ICC for those VOCs thought to 
have an environmental origin (Table S1).
Inflammatory mediators. Differential neutrophils were found to strongly correlate with total WCC (r 
(n = 47) = 0.90, p < 0.001) and weakly correlated with differential monocytes (r (n = 47) = 0.68, p < 0.001). Further-
more, the time-averaged (median) neutrophil concentration calculated per patient weakly correlated with stroke 
severity (NIHSS score; r (n = 20) = 0.72, p < 0.001). No significant correlations were found between inflammatory 
markers and stroke severity or  A2DS2 score based on either levels obtained within 24 h of stroke onset, time-
averaged concentrations or peak concentrations. However, peak plasma concentrations of CRP were found to 
correlate with peak levels of IL-6 (r (n = 20) = 0.78, p < 0.001).
The inflammatory mediators CRP and IL-6 changed significantly over time (CRP H = 19.29, p < 0.001; IL-6 
H = 11.02, p = 0.012, Fig. 2). Post-hoc testing confirmed the difference between the means of the 24 h and 5–7 days 
timepoints (CRP p < 0.0001, IL-6 p = 0.007).
Breath metabolites. Table  S1 shows details of the 46 VOCs that were targeted across breath sam-
ples (n = 47), representing multiple chemical classes. There was a significant difference between the 24 h and 
13–15 days timepoints for α-pinene (p = 0.015) and between 24 h and 5–7 days for decanal (p = 0.041), as shown 
in Fig. 2. A paired t-test confirmed the significant change in abundance for decanal in patients sampled at both 
24 h and 5–7 days timepoints (n = 8, t = 4.012, df = 5, p = 0.0007). Results for all breath VOCs are summarised in 
Table S2.
Blood plasma metabolites. Plasma metabolite sample (n = 56) data processing generated 2420 mass spec-
tral features (individual ion intensities annotated with m/z and retention time values). Molecular networking 
was used to identify compounds which drove temporal variation between blood plasma metabolites. Out of 2420 
features, 357 could be mapped to empirical IDs (tentative metabolite IDs) and 112 were selected based on the 
significance between timepoints (p < 0.05). This is visualised in Manhattan plots (supplementary Fig. S2). The 
Figure 2.  Boxplots (with median line, and whiskers of mininum and maximum value) annotated with Dunn’s 
test p values showing timepoint group differences for CRP concentration (top left, 24 h = 19; 3 days = 18; 
5–7 days = 13; 13-15 days = 6), IL-6 concentration (top right, 24 h = 19; 3 days = 18; 5–7 days = 13; 13–15 days = 6), 
breath α-pinene peak area (bottom left, 24 h = 13; 3 days = 9; 5–7 days = 12; 13–15 days = 11), and breath decanal 
peak area (bottom right, 24 h = 13; 3 days = 7; 5–7 days = 8; 13–15 days = 9). IS: internal standard.
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network map in supplementary Fig. S3 illustrates clustered groups with concerted metabolite activities. Of the 
112 features significantly different between timepoints, 11 features with empirical IDs (equivalent to MSI level 
2, i.e., accurate mass only) were mapped to metabolic pathways after a permutation test (p < 0.05). Table 2 shows 
the top metabolic pathways ordered by significance and the empirical IDs associated with each metabolic path-
way. Molecular networking provided two possible identities for the significant feature 176.0315 × 1.37: monode-
hydroascorbate and glucurono-6,3-lactone. The features that were linked to significant empirical IDs and likely 
metabolite candidates are listed in Table 3.
A PC-DFA classification model used 2 discriminant functions and 15 PCs selected from model parameter 
cross validation based on the 4 timepoint groups (24 h, 3 days, 5–7 days, and 13–15 days). The PC-DFA scores 
plot (the left-hand side of Fig. 3) illustrates a shift through timepoints: 24 h, 3 days and 5–7 days on the first dis-
criminant function, whilst the second discriminant function separates timepoint 13–5 days from the first three.
Presented on the right-hand side of Fig. 3 are the loadings for EIDs associated with the molecular network 
analysis. Metabolites associated with specific biochemical pathways appear to cluster in regions of the loadings 
plot, suggesting similar patterns in time profiles for these metabolites. In general, metabolites with negative 
loadings influence the 24 h timepoint. According to PC-DFA loadings for the first discriminant function, all of 
the significant features selected by the network analysis are related to peak concentrations at 24 h (immediately 
after stroke onset), with the exception of E18 (tetracosapentaenoyl carnitine) which relates to the 13–15 days 
timepoint.
Of the features identified in the network analysis, 549.3797 × 13.29 and 550.3917 × 13.60 had the most neg-
ative values on the first discriminant function, identified as the  [M]+ and [M +  1]+ adducts of platelet acti-
vating factor (plotted alongside significant EIDs in Fig. 3). This is closely followed by 532.3787 × 13.83 and 
258.1126 × 12.97, identified as the [M +  Na]+ and  [M]+ adducts of 1-Alkyl-2-lyso-sn-glycero-3-phosphocholine 
Table 2.  Top metabolite pathways associated with significant differences between timepoints. EID , Empirical 
ID; Pathway size , number of features associated with each pathway; EID overlap , features within the pathway 
which are significant.
Pathways Pathway size p value EID overlap
Carnitine shuttle 20 0.00025 E18,E83,E286,E165,E68,E258
Saturated fatty acids β-oxidation 2 0.00084 E286,E49
D4&E4-neuroprostanes formation 4 0.00462 E96,E311
Ascorbate (Vitamin C) and Aldarate Metabolism 8 0.02101 E96,E311
3-oxo-10R-octadecatrienoate β-oxidation 8 0.02101 E189, E304
Purine metabolism 9 0.02849 E96, E311
Phosphatidylinositol phosphate metabolism 2 0.03496 E49
Table 3.  List of features with metabolite identifications from molecular networking analysis, with Pearson’s 
correlation coefficients for inflammatory markers and breath decanal, and PC-DFA loadings.
Feature Predicted metabolite identification (MSI level 2) Pearson’s r Timepoint – KW
ID (m/z × RT/[min])
Empirical 




E165, E83 Tetradecanoyl carnitine
[M]+ 3.8 – – − 0.38(p = 0.036) – 18.8 0.018
372.3142 × 11.50 [M +  H]+ 9.1 − 0.33(p = 0.016) –
− 0.40
(p = 0.027) – 16.3 0.035
427.3657 × 12.20 E68 Stearoyl carnitine [M]+ 1.2 – – − 0.36(p = 0.044) – 15.8 0.039
502.3846 × 13.10
E18 Tetracosapentaenoyl carnitine




(p = 0.049) – 16.0 0.039
501.3815 × 13.11 [M]+ 0.6 0.39(p = 0.003)
0.35
(p = 0.008) – – 5.8 0.342
399.3339 × 11.69 E286 Palmitoyl carnitine [M]+ 2.5 – – – – 19.8 0.015
526.3817 × 13.49 E258 Tetracosatetraenoyl carnitine [M +  Na]
+ 9.5 − 0.41(p = 0.002)
− 0.41
(p = 0.002) – – 21.3 0.008
256.2378 × 11.80 E49 Hexadecanoate (n-C16:0) [M]
+ 9.4 − 0.27(p = 0.049)
− 0.29
(p = 0.033) – – 21.3 0.015
176.0315 × 1.37
E96 Monodehydroascorbate [M +  H]+ 0.6
– – – –
16.2 0.035
E311 Glucurono-6,3-lactone [M]+ 3.4 16.2 0.035
265.1801 × 11.76 E304 8-Hydroxy-hexadeca-2E,6E,10Z-trienoate [M]
+ 1.1 – – – – 23.5 0.008
237.1482 × 10.78 E189 6-Hydroxy-tetradeca-2E,4E,8Z-trienoate [M]
+ 3.8 – – − 0.48(p = 0.007) – 28.3 0.003
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and sn-Glycero-3-phosphocholine respectively. These glycerophosphocholines may be intermediates in the syn-
thesis and metabolism of platelet activating factor. The next most negative loadings on the first discriminant 
function are the acyl carnitines E258, E23 and E116, plotted in Fig. 3 and listed in Table S2, as well as feature 
284.2695 × 12.11, identified as the  [M+] adduct of octadecanoate (n-C18:0).
The most positive value for the first discriminant function was for feature 327.22 × 16.04, the  [M]+ adduct of 
12,13-epoxy-9-hydroperoxy-10E-octadecenoate, followed by 445.3346 × 13.32 and 432.3594 × 13.64, identified 
as the  [M]+ adducts of 13’-carboxy-γ-tocopherol and 13’-hydroxy-γ-tocopherol respectively.
For the second discriminant function, the most negative loadings were associated with 4-hydroperoxy-
2-nonenal and several features identified as fatty acids: 297.2453 × 13.74, 279.2343 × 14.5, 279.2346 × 13.73, 
280.2378 × 13.73 and 282.2534 × 13.85 assigned to the [M +  H]+ adducts of (13S)-Hydroxyoctadecadienoic acid 
and (9Z,12Z,15Z)-Octadecatrienoic acid and the  [M]+ adducts of α-Linolenic acid and (9Z)-Octadecenoic acid. 
The most positive loadings were 370.238 × 13.82 identified as the [M +  H+] adduct of prostaglandin G1 and 
414.2736 × 13.6 and 413.2699 × 19.07 identified as the [M +  1]+ and  [M]+ adducts 11’-carboxy-α-tocotrienol.
Figure 4 shows example box and whisker plots for metabolites selected from the loadings plot in Fig. 3. 
Features were selected to represent different pathways highlighted by molecular networking. There were no 
significant differences between metabolite levels when classified by stoke sub-type (posterior, total anterior and 
partial anterior circulation infarction), although sub-group sample sizes were small (Table 1). Future studies are 
therefore necessary in order to fully explore the impact that stroke vascular territory and mechanism may have 
on the circulating metabolome.
Correlation between blood plasma metabolites, inflammatory mediators and breath metabo-
lites. To generate the two dimensional correlation plot presented in Fig. 5, VOCs were analysed for correla-
tions with each other and with contemporaneously sampled CRP and IL-6 concentrations (n = 37). It is evident 
upon examination of Fig. 5 that VOCs of the same class (e.g. hydrocarbons) in many cases appear to correlate, in 
contrast to isoprene which showed a negative correlation with most hydrocarbons. The most negative isoprene 
correlation was with longifolene (r = − 0.65, p < 0.001). The top three positive correlations with CRP were for 
decanal (r = 0.38, p = 0.024), benzaldehyde (r = 0.34, p = 0.039) and pyridine (r = 0.28, p = 0.093). The top three 
negative correlations with CRP were observed for 1,4-dioxane (r = − 0.50, p = 0.002), 2-pentanone (r = − 0.40, 
p = 0.014) and hexane (r = − 0.29, p = 0.082). With regard to IL-6, the strongest positive correlation was with deca-
nal (r = 0.45, p = 0.005), followed by benzyl alcohol (r = 0.25, p = 0.136) and tetralin (r = 0.19, p = 0.260), whereas 
the top three negatively correlated VOCs were nonane (r = − 0.40, p = 0.013), heptanal (r = − 0.40, p = 0.013) and 
nonanal (r = − 0.40, p = 0.014).
Of the 2420 MS features obtained following data processing of the blood plasma metabolites, 36 were found 
to significantly correlate with CRP and 53 with IL-6 (p value < 0.05) in contemporaneously acquired samples 
(n = 37), as shown in supplementary tables (Table S4 and S5). Of the features listed in Table S4, only 3 were 
identified in the network analysis: 200.1047 × 1.24, 470.3196 × 12.33 and 327.2313 × 13.17 which were tenta-
tively assigned to Glutamyl-β-aminopropiononitrile, eicosatetranoyl carnitine and arachidonic acid, respectively. 
The acyl carnitine was negatively correlated with CRP (r = − 0.38, p = 0.038), whilst the other two compounds 
were positively correlated r = 0.45 (p = 0.001) and 0.38 (p = 0.041), respectively). Eicosatetranoyl carnitine is 
also listed in Table S5 and significantly correlates with IL-6 (r = − 0.39, p = 0.03) along with 3 other features: 
442.2903 × 12.83, 507.3693 × 13.35, 363.2789 × 15.86, assigned to stearidonyl carnitine, Lysophosphatidylcho-
line and 12-hydroxyarachidonylethanolamide (with r = 0.50 (p = 0.002), − 0.39 (p = 0.038) and 0.37 (p = 0.050, 
respectively).
The top 3 correlations between peak levels of metabolites identified by molecular networking and stroke 
severity (NIHSS score) corresponded to the features: 307.1909 × 11.33 (r(20) = 0.51, p = 0.022), 550.3917 × 13.6 
Figure 3.  (Left) PC-DFA scores plot with blood plasma samples (n = 56) coloured by timepoint groups and 
(right) loadings plot showing EIDs from the molecular network analysis coloured by biochemical pathway. The 
significant EIDs listed in Table 3 are encircled in red. Details of all EIDs are listed in Table S3.
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(r(20) = 0.51, p = 0.022) and 190.0121 × 1.41 (r(20) = 0.49, p = 0.028). These were assigned to the [M +  H]+ adduct of 
3-oxo-10-hydroxy-octadeca-6E,8E,12Z-trienoate, the  [M]+ adduct of platelet activating factor and the [M +  Na]+ 
adduct of quinolinate. The features that correlated most strongly with  A2DS2 score include those assigned to 
3-oxo-10-hydroxy-octadeca-6E,8E,12Z-trienoate and quinolinate (r(20) = 0.68, p < 0.001 and r(20) = 0.62, 
p = 0.003, respectively) and tetradecanoyl carnitine (r(20) = 0.62, p = 0.007).
Correlations between plasma metabolite features and breath VOCs were also assessed. Features with sig-
nificant correlations (p < 0.05) with at least one breath VOC were extracted. A table of Pearson’s correlation 
coefficients from 816 blood plasma features with 46 breath VOCs is shown in supplementary file S6. VOC 
functional groups highly correlate with plasma features, for example with alkanes and terpenes (plasma feature 
retention time range of feature 757.6288 × 16.93, 7.24–7.65, and 17.86–19.61 min). These data suggest some 
blood plasma metabolites are directly linked to VOCs exhaled in breath. The features most correlated with 
decanal are 165.1651 × 15.00 (r = − 0.682, p < 0.001), 435.3097 × 19.58 (r = 0.595, p < 0.001). Pearson correlation 
coefficients for the significant empirical identities generated in the network analysis are shown in Table 3 for 
CRP, IL-6, decanal, and α-pinene.
Discussion
Recent studies have demonstrated the potential that breath biomarkers have in monitoring inflammatory 
 diseases39. However, establishing the endogenous metabolic relationship of many volatile breath components is 
still far from  complete40 and challenges remain in standardising sampling and  analysis41. In this study we investi-
gated exhaled VOC and plasma metabolite changes in patients over 15 days after stroke onset. To the best of our 
knowledge, this is the first study to perform breath analysis of volatiles in stroke patients. We have demonstrated 
that recruitment is feasible, and sampling well-tolerated, in dysphagic patients and in patients with moderate or 
severe stroke, supporting further breath studies in acute stroke.
Exhaled decanal levels steadily increased over the first 7 days after stroke onset, in parallel to blood CRP 
and IL-6 concentration, suggesting that decanal is likely associated with systemic inflammation. Decanal was 
Figure 4.  Boxplots (with median line, and whiskers of mininum and maximum value) for selected plasma 
metabolites showing change in intensity over time following stroke onset.
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identified to MSI level 2 based on fragmentation pattern and retention index and targeted based on exact mass 
fragment. Although the most notable aldehyde marker of oxidative stress resulting from lipid peroxidation is 
 malondialdehyde42, short chain aldehydes have been identified in the breath of individuals with chronic inflam-
matory diseases such as  asthma43. Exhaled breath concentrations of decanal and other short chain aldehydes were 
also reported to increase in patients with oesophageal and gastric  adenocarcinoma44. No other volatiles targeted 
in this study (including similar short chain aldehydes) mirrored inflammation markers in showing significant 
differences between the 24 h and 5–7 days timepoints.
The only other VOC that exhibited significant differences over the time course of this study was α-pinene, 
which decreased steadily across timepoints 24 h to 13–15 days and correlated well with other monoterpenes (e.g., 
camphene and 3-carene). As well as being detected in headspace during in vitro studies of several pathogenic 
species (e.g., Aspergillus fumigatus45) and in studies that identified exhaled markers of infectious  diseases16, 
monoterpenes are ubiquitous in the ambient environment and are found in many food items. Changes in lifestyle 
following hospital admission are likely to be reflected in the volatile profile of patients’ breath, and decreasing 
exhaled α-pinene concentrations could be an example of this. Little is known on how changes to environment 
and diet may affect the breath of patients during medium and long-term hospital stay. Furthermore, washout of 
Figure 5.  Correlations matrix plot of breath VOCs and inflammatory markers (CRP and IL-6) ordered by 
hierarchical clustering. Pearson’s correlation coefficients are shown by colour strength and circle size, where 1 is 
strong positive correlation, -1 is strong negative correlation, and 0 is no correlation.
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VOCs from the body is known to be compound dependent and  complex46,47 and as studies have observed the 
storage of lipophilic compounds in the  body48, changes to the exposome may manifest as gradual changes in 
exhaled breath composition.
Supervised multivariate analysis illustrated that plasma metabolite profiles could be classified by post-stroke 
time course. Annotation of plasma metabolite features with their putative pathways and identities were predicted 
from metabolic network analysis. Five metabolites associated with the carnitine shuttle were putatively identi-
fied as tetradecanoyl carnitine, stearoylcarnitine, tetracosapentaenoyl carnitine, tetracosatetraenoyl carnitine 
and L-palmitoylcarnitine, with the latter additionally involved in saturated fatty acid β-oxidation. Carnitine 
transports fatty acids from stores into mitochondria for energy production, and have been found to be down 
regulated in frailty in the  elderly49. Studies have shown elevated serum acyl carnitine in stroke patients on 
admission compared to healthy  controls50,51. Our results are consistent with an increase in energy requirements 
symptomatic of ischemia followed by gradually depleted concentrations after stroke. However, one acyl carni-
tine, tetracosapentaenoyl carnitine continued to increase throughout the duration of the sampling period. This 
conflicting behaviour is also reflected in the correlation coefficients calculated for acyl carnitines and IL-6, e.g., 
eicosatetranoyl negatively correlated whilst stearidonyl carnitine positively correlated with IL-6. In general, the 
time profiles for different acyl carnitines exhibit a diverse range, perhaps reflecting the numerous roles that acyl 
carnitines play in stroke recovery for energy production and neuroprotection.
Peak levels of platelet activating factor identified in the network analysis were found to weakly correlate with 
stroke severity. The initial peak in levels of platelet activating factor and strong downward trend that followed 
was mirrored by several acyl carnitines and octadecanoate (n-C18:0). Another short chain fatty acid, hexade-
canoate (n-C16:0), is located near L-palmitoylcarnitine on the PC-DFA loadings plot, supporting their feature 
assignment and grouping by biochemical pathway. Platelet activating factor is known to be a potent mediator of 
inflammation and is synthesised in the injured  brain52.
Polyunsaturated fatty acids (PUFA) identified as 8(R)-hydroxy-hexadeca-2E,6E,10Z-trienoate (E55) and 
6(R)-hydroxy-tetradeca-2E,4E,8Z-trienoate (E9), are associated with 3-oxo-10R-octadecatrienoate β-oxidation. 
According to PC-DFA loadings, these PUFAs had a strong influence on the first discriminant function in the 
negative direction, and therefore were associated with 24 h timepoint (the first sample after stroke onset). Fur-
thermore, these PUFAs were negatively correlated to inflammatory markers and breath decanal which showed 
increased concentrations post-stroke, indicating a relationship between inflammatory markers, blood metabo-
lites, and breath volatiles. A study by Jiang et al.53 identified similar PUFAs that were predictive of stroke and 
found that concentrations were increased in serum compared to age and gender-matched controls. However, 
decreased levels of several fatty acids have also been associated with increased stroke risk. It is interesting to 
note that the other PUFAs identified in the network analysis peak at progressively later times according to their 
loadings, as depicted in Fig. 3.
Quinolinate is involved in tryptophan metabolism and is thought to be a neurotoxic metabolite produced in 
the kynurenine pathway originating from the catabolism of tryptophan by indolamine 2,3-dioxygenase, involved 
in inducing oxidative stress and activating NMDA receptor  activity54,55. Brouns et al. analysed TRP and its 
metabolites in stroke patients and found that 3-hydroxyanthranilate (and quinolinate as a direct precursor 
of 3-hydroxyanthranilate) significantly declined in concentration from admission  onwards55. They concluded 
tryptophan degradation, which also correlated with CRP, was predictive of acute stroke severity and long-term 
stroke outcome. This is consistent with our study which shows where quinolinate was found to correlate with 
NIHSS score.
Purinergic signalling is involved in ischemia and  stroke56 and stroke severity has been linked with elevation 
in blood purines (adenosine, inosine and xanthine)57. However, as yet another example of metabolic duality, 
decreased adenosine levels have also been  reported53 and both elevated and decreased glutamine levels have 
been previously observed in ischemic  stroke51,58,59. This is also reflected in the present study whereby feature 
176.0315 × 1.37 (attributed to monodehydroascorbate and glucurono-6,3-lactone) had negative loadings along 
the second discriminant function and peak levels were observed for the 24 h timepoint, whilst loadings for 
all other purine metabolites (guanine, inosine, urate, xanthine, adenosine and 5-Phospho-β-D-ribosylamine) 
were positive indicating that they peak at progressively later times. This biochemistry is complex, for example, 
monodehydroascorbate and glucurono-6,3-lactone are also involved in D4&E4-neuroprostanes formation and 
ascorbate and aldarate metabolism. Nevertheless, the conflicting results obtained in previous metabolomics 
studies may well reflect the metabolic dynamics of post-stroke inflammation and repair.
A range of VOCs were targeted in breath representing different chemical properties and potential pathways 
relating to their roles as metabolites. Through breath VOC intra-correlation analysis, we have shown that several 
exhaled compounds with similar structural chemistry correlate with one another, for example branched and 
straight chain alkanes or structural isomers of monoterpenes. Furthermore, several breath VOCs correlated 
well with both plasma CRP and with clusters of UHPLC features, supporting the view that certain volatiles are 
endogenously produced from metabolic processes.
Follow-on studies investigating stroke biomarkers or post-stroke complications such as stroke-associated 
pneumonia must consider increased sample sizes and appropriate non-stroke control comparisons. This can be 
achieved through multi-site or external validation studies. Improvements in analytical methodologies may also 
engender confidence in post-stroke prognostic biomarker development. Future studies may consider using a 
lipidomics approach as several lipid metabolites were identified. In addition, parallel methods with chromatog-
raphy phases suitable for hydrophilic compounds (e.g. HILIC or normal phase) will be advantageous to resolving 
polar metabolites and therefore compound identification for example features in this study with retention times 
under 2 min (E96, E311). It should be noted that our entry criteria were relatively strict, requiring participants 
to be recruited within 24 h of stroke onset, and at high risk of pneumonia, thus limiting the number of eligible 
participants. Whilst our findings relating to metabolomics and inflammation should only be applied to this 
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group, it is reasonable to assume that our main findings around feasibility could be extrapolated to those with 
less severe strokes and at later timepoints after onset.
Infections, particularly pneumonia, commonly complicate stroke and are associated with worse clinical out-
comes. Currently, there is a need for accurate biomarkers to guide prediction and treatment of stroke-associated 
pneumonia and inform prognosis. Due to the small sample size and modest  A2DS2 threshold, no patients devel-
oped CDC-confirmed stroke-associated pneumonia. Even in the absence of any confirmed pneumonia, our data 
provide preliminary insights into the relationships between peripheral inflammatory markers and metabolic 
pathways in acute stroke. The principles underlying our breath sampler have been further developed through the 
Breathe-Free  consortium60, and a commercial sampler based on this concept is now available, further facilitating 
larger scale clinical  studies27,61. Limited strategies are available to effectively prevent pneumonia in acute stroke, 
and antibiotic treatment when pneumonia is suspected remains the cornerstone of clinical management. Predict-
ing those at risk of pneumonia complicating stroke is critical in directing monitoring and potential preventive 
therapies as well as resource allocation.
Conclusion
We found changes in concentrations of endogenous metabolites over time which may be indicative of stroke-
associated inflammatory activity. We observed multiple positive and negative correlations across exhaled breath 
components and blood plasma metabolites which demonstrate a dynamic response, potentially a consequence 
of intrinsic neurotoxic and neuroprotective mechanisms. Metabolites from blood plasma and breath samples 
correlated with the established inflammatory markers CRP and IL-6. These results illustrate the complexity of the 
endogenous inflammatory cascade during evolution of acute and subacute stroke and into the recovery phase, 
and warrant future investigation towards potential clinical application.
Our study shows serial breath sampling is feasible and well-tolerated in patients with acute stroke. We have 
also explored relationships between plasma inflammatory markers, plasma metabolites, and breath volatiles 
which motivates additional multi-omics and multi-compartment analyses to confirm metabolic origins. Follow 
on studies are required to validate our results and to further explore the breath volatilome for novel biomarkers, 
particularly for predicting or diagnosing stroke-associated pneumonia and for prognostication.
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